Patient
SITE015-0227
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-05-30
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 102); relationship: NOT RELATED
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 99); relationship: NOT RELATED
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 86); relationship: NOT RELATED; serious criteria: hospitalization
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 83); relationship: not assessed
Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-03 (study day 64); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 47); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 46); relationship: NOT RELATED
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 27); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.